BIGG

Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Nirsevimab, Season 1

MMWR recomm. rep; 72 (34), 2023
Ano de publicação: 2023

A Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) review of the evidence for benefits and harms of the long-acting monoclonal antibody nirsevimab, (Beyfortus, Sanofi and AstraZeneca) for prevention of respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) in infants born during or entering their first RSV season was presented to the Advisory Committee on Immunization Practices (ACIP) on February 23, 2023. GRADE evidence type indicates the certainty in estimates from the available body of evidence. Evidence certainty ranges from high certainty to very low certainty [1].